Pipeline

Cullinan is advancing a broad and deep pipeline of eight targeted oncology programs that span a range of cancer indications and diverse technology platforms at various stages of development. Our focus is on first- and/or best-in-class potential molecules that activate the immune system or target key oncogenic drivers with the promise of single agent efficacy.

Program (Subsidiary/Project) 
Modality / MOA 
Discovery / Lead Optimization  IND-Enabling  Phase 1  Phase 2  Phase 3  Status 
CLN-081 (Pearl)
EGFR ex20 inhibitor
NSCLC with exon 20 insertion mutations
BTD received; Regulatory update Q1 ’22 
CLN-049 (Florentine)
FLT3 x CD3 bispecific
R/R AML
Clinical trial initiated Dec 2021 
CLN-619 (MICA)
Anti-MICA/B IgG1
Pan-cancer
Clinical trial initiated Dec 2021 
CLN-617 (Amber)
Collagen-binding IL12-IL2 fusion protein
Pan-cancer
IND-enabling studies 
CLN-978 (NexGem)
CD19 X CD3 X HSA trispecific
B-cell ALL, NHL
IND-enabling studies 
Jade
TCR-based therapy targeting a senescence and cancer-related protein pMHC complex
HPV+/RB-
IND-enabling studies 
Opal
PD-1 x CD137L fusion protein
Pan-cancer
Candidate selection 
HPK1
Potentially first-in-class protein degrader
Pan-cancer
Candidate selection